Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan for older adolescents and adults with osteogenesis imperfecta
ISRCTN13317811Phase 2Active, not recruiting
- Sponsor
- Sheffield Children's Hospital
- Start
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of losartan in osteogenesis imperfecta (OI) (3 arms), sponsored by Sheffield Children's Hospital. Primary endpoint: Percentage change in CTX over 24 weeks. Started Nov 2023; status: active, not recruiting.
02
Drugs
losartan
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on ISRCTN13317811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13317811.